Crossmark

Haploidentical versus matched unrelated donor transplantation with post-transplant cyclophosphamide: a platform-dependent machine learning analysis of donor age

Crossref DOI link: https://doi.org/10.1038/s41375-026-02903-8

Published Online: 2026-04-15

Update policy: https://doi.org/10.1007/springer_crossmark_policy

Authors

Mehta, Rohtesh S. https://orcid.org/0000-0002-8532-544X
Kanakry, Christopher G. https://orcid.org/0000-0002-7736-2056
Nawas, Mariam

Lazaryan, Aleksandr https://orcid.org/0000-0001-9605-6436
Kanakry, Jennifer A. https://orcid.org/0000-0001-9522-3618
Holtan, Shernan https://orcid.org/0000-0002-5054-9419
Al-Juhaishi, Taha

Rimando, Joseph Cataquiz

Singh, Anurag https://orcid.org/0000-0003-1114-9508
Saultz, Jennifer https://orcid.org/0000-0003-0024-9466
Mccurdy, Shannon R. https://orcid.org/0000-0002-2813-6781
Milano, Filippo https://orcid.org/0000-0003-3573-2159
License Information

Text and Data Mining valid from 2026-04-15

Version of Record valid from 2026-04-15
More Information

Article History

Received: 12 November 2025

Revised: 23 January 2026

Accepted: 24 February 2026

First Online: 15 April 2026

Competing interests

: RSM: consultancy for OrcaBio and expert opinion for Lumanity. AL: Sanofi: consultancy/honoraria/scientific advisory board, Incyte: consultancy/honoraria, Pierre Fabre: consultancy/honoraria. Other authors report no relevant conflicts of interest. SH: VITRAC Therapeutics (research funding), Incyte (research funding), CSL Behring (clinical trial adjudication), Sanofi (non-branded educational programming), MaaT Pharma (advisory board), Ossium (advisory board). TA-J: KITE Pharma and Stemline Therapeutics (advisory board).

Document is current

Any future updates will be listed below